The bill requires the Secretary of State to commission an independent review—led by a current or former High Court judge—into no‑fault financial assistance for people disabled by Covid‑19 vaccination and for next of kin where death followed shortly after vaccination. The review must assess medical, administrative and legal factors (including the current Vaccine Damage Payments Act 1979 and the 60% disablement threshold), report recommendations to Parliament, and prompt a government response.
Separately, the bill obliges the Secretary of State to bring forward concrete proposals for financial assistance within six months and to run a 12‑week public consultation on those proposals; it also inserts a new Limitation Act provision creating a six‑year time limit for personal injury and wrongful death claims tied to Covid‑19 vaccination (with specific rules about the date of knowledge). The Limitation amendment applies to England and Wales only.
At a Glance
What It Does
The bill directs a judge‑led independent review of no‑fault Covid‑19 vaccine compensation, requires the government to propose and consult on a support scheme within fixed deadlines, and amends the Limitation Act to create a six‑year claim period tied to 'date of knowledge' for vaccine injury and death claims. It also requires the review to examine the current Vaccine Damage Payments Act 1979 and whether its 60% disablement threshold and other criteria are fit for purpose.
Who It Affects
Directly affected parties include people who allege disablement after a Covid‑19 vaccine, bereaved next of kin, legal claimants and personal injury lawyers, and the Treasury (which would underwrite any compensation). Regulators (the MHRA) and the NHS are named review subjects because the bill requires assessment of their roles in identifying, publicising and treating adverse reactions.
Why It Matters
The bill sets a process to reconsider the UK's approach to vaccine injury redress: it could lead to a no‑fault compensation scheme with different eligibility and payment rules than the 1979 framework, change litigation windows for claimants, and create operational and fiscal obligations for government and health bodies. Practitioners need to track how the review defines causation, eligibility, and payment caps.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill creates two parallel streams: a near‑term, judge‑led independent review into no‑fault compensation for Covid‑19 vaccine injuries and a statutory timetable for government proposals and consultation on a compensation scheme. The review must be led by a current or former High Court judge and consider a wide set of questions: what types of injury have occurred after each vaccine used in the UK; whether the Vaccine Damage Payments Act 1979 (and specifically its 60% disablement threshold) still fits the range of conditions claimed today; whether next‑of‑kin payments should be available when death is proven to result from vaccination; and how the MHRA and the NHS have performed in identifying, publicising and treating adverse reactions.
The review must also consider whether compensation should be disregarded for Universal Credit purposes.
Timelines are explicit. The Secretary of State must appoint the reviewer quickly, have the reviewer produce a report, and lay that report before Parliament; the government must publish a response to the report.
Separately, within six months the Secretary of State must bring forward detailed proposals for financial assistance and consult them for 12 weeks, with a government response to that consultation required within a fixed period. The bill therefore forces a phased policy process: diagnosis (the review), design (the proposals and consultation), and political accountability (parliamentary laying and responses).On litigation, the bill amends the Limitation Act 1980 to create a bespoke six‑year limitation period for actions “in respect of personal injury or death following a Covid‑19 vaccination.” For personal injury claims the clock runs from the claimant’s date of knowledge; for death claims it starts from the later of the date of death or the date of knowledge of the person bringing the claim.
That change applies to England and Wales only, leaving the existing limitation rules unchanged in Scotland and Northern Ireland. This amendment will affect the timing of when people must bring court proceedings and will interact with any no‑fault payments the government eventually proposes.The bill is procedural rather than prescriptive about the shape of compensation: it does not itself set eligibility criteria, payment levels, or an upper limit on awards.
Instead it requires the review to consider whether an upper limit should exist and asks ministers to consult on concrete proposals. That leaves key design choices—how to define causation, what medical conditions qualify, whether psychological or multi‑system conditions are covered, and whether awards are taxable or counted against means‑tested benefits—to the forthcoming review and consultation.
The Five Things You Need to Know
The bill requires appointment of a current or former High Court judge to lead the independent review assessing no‑fault compensation for Covid‑19 vaccine injuries.
The review must examine the Vaccine Damage Payments Act 1979, including whether the 60% disablement threshold and current criteria cover conditions such as psychological illness, multi‑system inflammatory syndrome and autoimmune conditions.
The Secretary of State must bring forward compensation proposals within six months and run a 12‑week public consultation; the government must publish its consultation response within a fixed period thereafter.
The bill inserts a new Limitation Act provision creating a six‑year time limit for personal injury and wrongful death claims relating to Covid‑19 vaccination, measured from the claimant’s date of knowledge (and, for death claims, the later of date of death or date of knowledge), but that change applies only to England and Wales.
Proposals must explicitly include provision for next‑of‑kin payments where a death is proven to result from vaccination; the bill also requires the review to consider whether compensation should be disregarded for Universal Credit.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Judge‑led independent review of no‑fault compensation
Section 1 mandates an independent review led by a current or former High Court judge and sets the scope of that review. It lists specific matters the reviewer must consider—from the clinical profile of vaccine‑linked conditions to the effectiveness of the MHRA and NHS response—and requires the report to recommend legislative or policy changes. Practically, this provision forces expert judicial leadership on technical questions (medical, regulatory and benefit‑interaction) and creates short statutory deadlines for producing the report and a government response, tightening parliamentary scrutiny of whatever the reviewer finds.
Government must propose and consult on financial assistance
Section 2 obliges the Secretary of State to develop detailed proposals for financial assistance within six months of the Act and to consult the public and stakeholders for 12 weeks. The subsection explicitly requires inclusion of next‑of‑kin compensation in those proposals and mandates that the government lay its consultation response before Parliament within a specified period. This section turns the review’s findings into a forced policy exercise with formal public consultation, signalling that Parliament must see concrete design proposals rather than an open‑ended inquiry.
Special six‑year limitation rule for vaccine claims (England and Wales)
Section 3 amends the Limitation Act 1980 by inserting section 13A, which prescribes a six‑year limitation period for actions 'in respect of personal injury or death following a Covid‑19 vaccination.' For injury claims the period runs from the claimant’s date of knowledge; for death claims it runs from the later of date of death or the date of knowledge of the beneficiary. The provision also updates cross‑references in section 14 so the new rule is included in existing 'date of knowledge' definitions. Legally, this narrows (or clarifies) the time window for litigation connected to Covid‑19 vaccination in England and Wales and may interact with any compensation scheme the government chooses to create.
Extent, commencement and short title
Section 4 sets territorial scope and entry into force: the Act (other than the Limitation Act amendment) extends across the UK, while the limitation amendment applies only to England and Wales; the Act comes into force on royal assent and may be cited by the short title provided. The differential extent is consequential: claimants and courts in Scotland and Northern Ireland will continue to rely on their existing limitation regimes for Covid‑19 vaccine litigation until (or unless) equivalent rules are enacted there.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- People who allege serious disablement after a Covid‑19 vaccine — the bill creates an explicit pathway for a no‑fault compensation scheme to be designed and may lower barriers to financial assistance compared with pursuing tort claims.
- Next of kin of people who died shortly after vaccination — the bill requires proposals to include next‑of‑kin payments and makes that group a formal part of the review and consultation process.
- Patient advocacy and specialist clinicians — the review’s mandated focus on a broad set of conditions (including psychological and multi‑system disorders) gives these groups a clear forum to push for recognition of less‑conventional vaccine‑related harms.
- Public health policymakers — clarifying compensation policy and litigation windows can reduce legal uncertainty and allow officials to design outreach and record‑keeping practices to support both surveillance and potential claimants.
Who Bears the Cost
- The Treasury and taxpayers — any no‑fault payments that result from this process would create direct public expenditure and administrative costs borne by central government.
- Department of Health and NHS trusts — the bill requires scrutiny of NHS diagnosis and care pathways and could lead to resourcing pressure if the review or scheme requires enhanced diagnostics, specialist clinics, or ongoing treatment funding.
- Regulators (MHRA) and public bodies — the review evaluates MHRA’s role in identifying and publicising adverse reactions, which could lead to obligations for improved surveillance, reporting or communications with associated budgetary and reputational costs.
- Legal professionals and insurers — the Limitation Act change and the prospect of a new compensation scheme will alter litigation patterns, potentially reducing some private tort claims but increasing administrative claims and appeals that attract legal costs.
Key Issues
The Core Tension
The bill balances two legitimate goals that pull in different directions: providing accessible, no‑fault redress to people harmed after vaccination (which argues for low procedural barriers, broad eligibility, and possible disregard for means‑tested benefits) versus protecting public health programmes and public finances (which argues for tight eligibility, robust causation tests, and fiscal limits). Designing a scheme that compensates genuine harms without creating unsustainable costs or undermining vaccination confidence is the central dilemma.
The bill deliberately leaves the substantive design of compensation to the review and a subsequent consultation, which creates two implementation risks. First, tight statutory deadlines (appointment, report laying, consultation, and response windows) may force an expedited review process that cannot meaningfully resolve complex medical‑causation and entitlement questions; a judge‑led review can reach robust legal findings but will still need clinical panels and detailed data, which take time to assemble.
Second, by asking whether payments should be disregarded for Universal Credit, the bill invites difficult interactions between social security rules and compensatory logic—ignoring benefits tests protects recipients but raises fiscal cost; counting payments preserves benefit targeting but undermines the purpose of compensation.
On causation and scope, the reviewer must grapple with fundamentally contested scientific questions: temporal association is often easier to establish than causal attribution for conditions like autoimmune disease or multi‑system inflammatory syndromes. The bill requires consideration of psychological conditions alongside somatic illnesses, but it does not set evidentiary standards.
That gap risks divergent outcomes between a future no‑fault scheme (which may adopt lower causation thresholds) and civil courts (which require proof on the balance of probabilities). The Limitation Act amendment clarifies timing for litigation in England and Wales but raises questions about equitable treatment across the UK and about the practical meaning of 'date of knowledge' and 'shortly after vaccination'—terms the bill does not define.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.